Eli Lilly and Company


	About Us

	Business in NYC

	Industry Initiatives

	For International Businesses

	Central Business Districts (CBDs)

	Success Stories

	Facts & Figures

	Additional Business Resources

	Projects & Opportunities

	Real Estate

	Living in NYC

	Financing & Incentives

	Research, News & Publications

	Press Room

Success Stories

Bioscience

Eli Lilly and Company


	Our new location in New York City, with unprecedented access to academic research organizations, the latest research tools and our FIPNet (Fully Integrated Pharmaceutical Network) partners, will help us speed innovative medicines to patients.
	John Lechleiter, CEO, Eli Lilly and Company

1 of 1

BUSINESS NEED

At the beginning of this administration, NYCEDC began to study the field to identify obstacles to growing the bioscience industry and developed targeted responses to support the sector. As part of this effort, NYCEDC led the creation of the City's first research park on City controlled land. The project is being developed by Alexandria Real Estate Equities. After acquiring NYC based ImClone Systems for $6.5 billion, Eli Lilly was looking for a home to base translational research and development operations for its subsidiary as well as speeding up R & D.

SOLUTION

NYCEDC’s efforts help lead Eli Lilly to sign a long-term lease to occupy more than 90,000 square feet for a new oncology research headquarters for its subsidiary ImClone Systems. East River Science Park’s proximity to major research hospitals, such as the nearby New York University Langone Medical Center, will boost Eli Lilly’s exposure to scientific talent and help speed up R & D.